EMILY MOORE: Open Payments
NPI 1730579921 · ARKADELPHIA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$481 in 30 payments from 8 companies in 2025. Trend: 2023 $595 · 2024 $446 · 2025 $481
Food & beverage: $481
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 13 | $135 |
| Dexcom, Inc. | 5 | $99 |
| AstraZeneca Pharmaceuticals LP | 4 | $70 |
| Abbott Laboratories | 3 | $54 |
| ABBVIE INC. | 2 | $45 |
| ABIOMED | 1 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: Dexcom G6 Transmitter, JARDIANCE, MOUNJARO, FREESTYLE LIBRE 3, BREZTRI, FARXIGA, UBRELVY, REXULTI.
Industry payments across AR — which companies pay providers there.
